Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 176

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Antiviral Resistance and Correlates of Virologic Failure in the first Cohort of HIV-Infected Children Gaining Access to Structured Antiretroviral Therapy in Lima, Peru: A Cross-Sectional Analysis

Open access
Rath, Barbara A, von Kleist, Max, Castillo, Maria E, Kolevic, Lenka, Caballero, Patricia, Soto-Castellares, Giselle, Amedee, Angela M, Robinson, James E, Katzenstein, David K, Van Dyke, Russell B, Oberhelman, Richard A·2013·BMC Infectious Diseases

Abstract

BACKGROUND: The impact of extended use of ART in developing countries has been enormous. A thorough understanding of all factors contributing to the success of antiretroviral therapy is required. The current study aims to investigate the value of cross-sectional drug resistance monitoring using DNA and RNA oligonucleotide ligation assays (OLA) in treatment cohorts in low-resource settings. The study was conducted in the first cohort of children gaining access to structured ART in Peru. METHODS: Between 2002-5, 46 eligible children started the standard regimen of AZT, 3TC and NFV Patients had a median age of 5.6 years (range: 0.7-14y), a median viral load of 1.7·105 RNA/ml (range: 2.1·10(3) - 1.2·10(6)), and a median CD4-count of 232 cells/μL (range: 1-1591). Of these, 20 patients were classified as CDC clinical category C and 31/46 as CDC immune category 3. At the time of cross-sectional analysis in 2005, adherence questionnaires were administered. DNA OLAs and RNA OLAs were performed from frozen PBMC and plasma, RNA genotyping from dried blood spots. RESULTS: During the first year of ART, 44% of children experienced virologic failure, with an additional 9% failing by the end of the second year. Virologic failure was significantly associated with the number of resistance mutations detected by DNA-OLA (p < 0.001) during cross-sectional analysis, but also with low immunologic CDC-scores at baseline (p < 0.001). Children who had been exposed to unsupervised short-term antiretrovirals before starting structured ART showed significantly higher numbers of resistance mutations by DNA-OLA (p = 0.01). Detection of M184V (3TC resistance) by RNA-OLA and DNA-OLA demonstrated a sensitivity of 0.93 and 0.86 and specificity of 0.67 and 0.7, respectively, for the identification of virologic failure. The RT mutations N88D and L90M (NFV resistance) detected by DNA-OLA correlated with virologic failure, whereas mutations at RT position 215 (AZT resistance) were not associated with virologic failure. CONCLUSIONS: Advanced immunosuppression at baseline and previous exposures to unsupervised brief cycles of ART significantly impaired treatment outcomes at a time when structured ART was finally introduced in his cohort. Brief maternal exposures to with AZT +/- NVP for the prevention of mother-to-child transmission did not affect treatment outcomes in this group of children. DNA-OLA from frozen PBMC provided a highly specific tool to detect archived drug resistance. RNA consensus genotyping from dried blood spots and RNA-OLA from plasma consistently detected drug resistance mutations, but merely in association with virologic failure.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1471-2334-13-1

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 50

  1. UNAIDS: Report on the Global AIDS Epidemic - Executive Summary. 2004, Geneva, Switzerland: UNAIDS - Joint United Nations Programme on HIV/AIDS: Edited by HIV/AIDS U-JUNPo, 1-22.
  2. Hainaut M, Ducarme M, Schandene L, Peltier CA, Marissens D, Zissis G, Mascart F, Levy J: Age-related immune reconstitution during highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J. 2003, 22 (1): 62-69. 10.1097/00006454-200301000-00016. · doi:10.1097/00006454-200301000-00016
  3. Curioso WH, Kepka D, Cabello R, Segura P, Kurth AE: Understanding the facilitators and barriers of antiretroviral adherence in Peru: a qualitative study. BMC Public Health. 2010, 10: 13-10.1186/1471-2458-10-13. · DOI
  4. Franke MF, Murray MB, Munoz M, Hernandez-Diaz S, Sebastian JL, Atwood S, Caldas A, Bayona J, Shin SS: Food Insufficiency is a Risk Factor for Suboptimal Antiretroviral Therapy Adherence among HIV-Infected Adults in Urban Peru. AIDS Behav. 2011, 15 (7): 1483-1489. 10.1007/s10461-010-9789-6. · DOI
  5. Franke MF, Munoz M, Finnegan K, Zeladita J, Sebastian JL, Bayona JN, Shin SS: Validation and abbreviation of an HIV stigma scale in an adult spanish-speaking population in urban Peru. AIDS Behav. 2010, 14 (1): 189-199. 10.1007/s10461-008-9474-1. · DOI
  6. Esteban PM, Thahn TG, Bravo JF, Roca LK, Quispe NM, Montano SM, Zunt JR: Malnutrition associated with increased risk of peripheral neuropathy in Peruvian children with HIV infection. J Acquir Immune Defic Syndr. 2009, 52 (5): 656-658. · doi:10.1097/qai.0b013e3181bb268d
  7. Willig JH, Echevarria J, Westfall AO, Iglesias D, Henostroza G, Seas C, Mugavero MJ, Allison J, Paz J, Hernandez F, et al: Durability of initial antiretroviral therapy in a resource-constrained setting and the potential need for zidovudine weight-based dosing. J Acquir Immune Defic Syndr. 2010, 53 (2): 215-221. 10.1097/QAI.0b013e3181bc0f10. · doi:10.1097/qai.0b013e3181bc0f10
  8. Shin S, Munoz M, Zeladita J, Slavin S, Caldas A, Sanchez E, Callacna M, Rojas C, Arevalo J, Sebastian JL, et al: How does directly observed therapy work? The mechanisms and impact of a comprehensive directly observed therapy intervention of highly active antiretroviral therapy in Peru. Health Soc Care Community. 2011, 19 (3): 261-271. 10.1111/j.1365-2524.2010.00968.x. · DOI
  9. Pontali E, Feasi M, Toscanini F, Bassetti M, De Gol P, Nuzzolese A, Bassetti D: Adherence to combination antiretroviral treatment in children. HIV Clin Trials. 2001, 2 (6): 466-473. 10.1310/7BNT-UTL0-UPPF-CA9H. · doi:10.1310/7bnt-utl0-uppf-ca9h
  10. Cesar C, Shepherd BE, Krolewiecki AJ, Fink VI, Schechter M, Tuboi SH, Wolff M, Pape JW, Leger P, Padgett D, et al: Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America. PLoS One. 2010, 5 (6): e10490-10.1371/journal.pone.0010490. · doi:10.1371/journal.pone.0010490
  11. Munoz M, Bayona J, Sanchez E, Arevalo J, Sebastian JL, Arteaga F, Guerra D, Zeladita J, Espiritu B, Wong M, et al: Matching Social Support to Individual Needs: A Community-Based Intervention to Improve HIV Treatment Adherence in a Resource-Poor Setting. AIDS Behav. 2011, 15 (7): 1454-1464. 10.1007/s10461-010-9697-9. · DOI
  12. Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick M, Musoke P, Fleming T: Glenn Fowler M, Mofenson LM et al.: Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS. 2001, 15 (15): 1951-1957. 10.1097/00002030-200110190-00006. · doi:10.1097/00002030-200110190-00006
  13. Wang ME, Castillo ME, Montano SM, Zunt JR: Immune reconstitution inflammatory syndrome in human immunodeficiency virus-infected children in Peru. Pediatr Infect Dis J. 2009, 28 (10): 900-903. 10.1097/INF.0b013e3181a4b7fa. · doi:10.1097/inf.0b013e3181a4b7fa
  14. MINSA: Aprobación de la directiva. 2002, In. Lima, Peru: Ministerio de Salud del Peru (MINSA): Tratamiento Antiretroviral en los niños infectados por el VIH
  15. MINSA: Guía Nacional de Manejo del Niño infectado por el VIH. 1999, In. Lima: Ministerio de Salud del Peru (MINSA)
  16. DIRECTIVA No. 020 - 2003-MINSA/DGSP-DEAIS-V.01: 2003, [ http://www.sgcnnavih.cepesju.org/Normativas/DIRECTIVA_020-2003-MINSA_DGSP-DEAIS-V.01.pdf ] · doi:10.1088/1126-6708/2003/01/020
  17. Soria J, Bull M, Mitchell C, Rosa AL, Dross S, Kraft K, Coombs R, Ticona E, Frenkel L: Transmitted HIV Resistance to First-Line Antiretroviral Therapy in Lima. AIDS Res Hum Retroviruses. 2012, 28 (4): 333-8. 10.1089/aid.2011.0131. · doi:10.1089/aid.2011.0131
  18. Ellis GM, Mahalanabis M, Beck IA, Pepper G, Wright A, Hamilton S, Holte S, Naugler WE, Pawluk DM, Li CC, et al: Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma. J Clin Microbiol. 2004, 42 (8): 3670-3674. 10.1128/JCM.42.8.3670-3674.2004. · doi:10.1128/jcm.42.8.3670-3674.2004
  19. Schinazi RF, Schlueter-Wirtz S, Stuyver L: Early detection of mixed mutations selected by antiretroviral agents in HIV-infected primary human lymphocytes. Antivir Chem Chemother. 2001, 12 (Suppl 1): 61-65.
  20. Frenkel LM, Wagner LE, Atwood SM, Cummins TJ, Dewhurst S: Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to, and didanosine. J Clin Microbiol. 1995, 33 (2): 342-347. · DOI
  21. Cassol SA, Read S, Weniger BG, Pilon R, Leung B, Mo T: Diagnosis and Direct Automated Sequencing of HIV-1 From Dried Blood Spots (DBS) Collected on Filter Paper. Methods Mol Med. 1999, 17: 125-138.
  22. Sherman GG, Stevens G, Jones SA, Horsfield P, Stevens WS: Dried blood spots improve access to HIV diagnosis and care for infants in low-resource settings. J Acquir Immune Defic Syndr. 2005, 38 (5): 615-617. 10.1097/01.qai.0000143604.71857.5d. · DOI · Paper page
  23. Youngpairoj AS, Masciotra S, Garrido C, Zahonero N, de Mendoza C, Garcia-Lerma JG: HIV-1 drug resistance genotyping from dried blood spots stored for 1 year at 4 degrees C. J Antimicrob Chemother. 2008, 61 (6): 1217-1220. 10.1093/jac/dkn100. · doi:10.1093/jac/dkn100
  24. Mitchell C, Jennings C, Brambilla D, Aldrovandi G, Amedee AM, Beck I, Bremer JW, Coombs R, Decker D, Fiscus S, et al: Diminished human immunodeficiency virus type 1 DNA yield from dried blood spots after storage in a humid incubator at 37 degrees C compared to −20 degrees C. J Clin Microbiol. 2008, 46 (9): 2945-2949. 10.1128/JCM.00359-08. · doi:10.1128/jcm.00359-08
  25. Mitchell C, Kraft K, Peterson D, Frenkel L: Cross-contamination during processing of dried blood spots used for rapid diagnosis of HIV-1 infection of infants is rare and avoidable. J Virol Methods. 2010, 163 (2): 489-491. 10.1016/j.jviromet.2009.10.016. · DOI
  26. CDC: Revised Classification System for Human Immunodeficiency Virus Infection in Children Less Than 13 Years of Age. MMWR. 1994, 43 (12): 1-10.
  27. Farley JJ, Montepiedra G, Storm D, Sirois PA, Malee K, Garvie P, Kammerer B, Naar-King S, Nichols S: Assessment of adherence to antiretroviral therapy in perinatally HIV-infected children and youth using self-report measures and pill count. J Dev Behav Pediatr. 2008, 29 (5): 377-384. 10.1097/DBP.0b013e3181856d22. · DOI
  28. Naar-King S, Montepiedra G, Nichols S, Farley J, Garvie PA, Kammerer B, Malee K, Sirois PA, Storm D: Allocation of family responsibility for illness management in pediatric HIV. J Pediatr Psychol. 2009, 34 (2): 187-194. · doi:10.1093/jpepsy/jsn065
  29. Henning TR, Lacour N, Amedee AM: Efficient methodologies for sensitive HIV-1 RNA quantitation from plasma and vaginal secretions. J Clin Virol. 2009, 46 (4): 309-313. 10.1016/j.jcv.2009.08.015. · doi:10.1016/j.jcv.2009.08.015
  30. Beck IA, Mahalanabis M, Pepper G, Wright A, Hamilton S, Langston E, Frenkel LM: Rapid and sensitive oligonucleotide ligation assay for detection of mutations in human immunodeficiency virus type 1 associated with high-level resistance to protease inhibitors. J Clin Microbiol. 2002, 40 (4): 1413-1419. 10.1128/JCM.40.4.1413-1419.2002. · doi:10.1128/jcm.40.4.1413-1419.2002
  31. Shafer RW, Hertogs K, Zolopa AR, Warford A, Bloor S, Betts BJ, Merigan TC, Harrigan R, Larder BA: High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. J Clin Microbiol. 2001, 39 (4): 1522-1529. 10.1128/JCM.39.4.1522-1529.2001. · doi:10.1128/jcm.39.4.1522-1529.2001
  32. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer R, Wensing AM, Richman DD: 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2011, 19 (4): 156-164.
  33. Crabtree-Ramirez B, Caro-Vega Y, Shepherd BE, Wehbe F, Cesar C, Cortes C, Padgett D, Koenig S, Gotuzzo E, Cahn P, et al: Cross-sectional analysis of late HAART initiation in Latin America and the Caribbean: late testers and late presenters. PLoS One. 2011, 6 (5): e20272-10.1371/journal.pone.0020272. · doi:10.1371/journal.pone.0020272
  34. Alarcon JO, Freimanis-Hance L, Krauss M, Reyes MF, Cardoso CA, Mussi-Pinhata MM, Cardoso E, Alarcon JO, Freimanis-Hance L, Krauss M, Reyes MF, Cardoso CA, Mussi-Pinhata MM, Cardoso E, Alarcon JO, Freimanis-Hance L, Krauss M, Reyes MF, Cardoso CA, Mussi-Pinhata MM, Cardoso E: Opportunistic and other infections in HIV-infected Children in Latin America compared to a similar cohort in the United States. AIDS Res Hum Retroviruses. 2012, 28 (3): 282-8. 10.1089/aid.2011.0057. · doi:10.1089/aid.2011.0057
  35. Patel K, Hernan MA, Williams PL, Seeger JD, McIntosh K, Dyke RB, Seage GR: Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting. Clin Infect Dis. 2008, 46 (11): 1751-1760. 10.1086/587900. · DOI
  36. Feucht UD, Forsyth B, Kruger M: False-positive HIV DNA PCR testing of infants: Implications in a changing epidemic. S Afr Med J. 2012, 102 (3): 149-152. · doi:10.7196/samj.4951
  37. Frank M, von Kleist M, Kunz A, Harms G, Schutte C, Kloft C: Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes. Antimicrobial agents and chemotherapy. 2011, 55 (12): 5529-5540. 10.1128/AAC.00741-11. · doi:10.1128/aac.00741-11
  38. Garcia PJ, Vargas JH, Caballero NP, Calle VJ, Bayer AM: An e-health driven laboratory information system to support HIV treatment in Peru: E-quity for laboratory personnel, health providers and people living with HIV. BMC Med Inform Decis Mak. 2009, 9: 50-10.1186/1472-6947-9-50. · DOI
  39. MINSA: A Step Forward in the FIght Against AIDS. 2006, In. Lima: Ministerio de Salud del Peru (MINSA): The first two years of universal access to antiretroviral treatment in Peru
  40. Aldridge RW, Iglesias D, Caceres CF, Miranda JJ: Determining a cost effective intervention response to HIV/AIDS in Peru. BMC Public Health. 2009, 9: 352-10.1186/1471-2458-9-352. · DOI
  41. Tuboi SH, Schechter M, McGowan CC, Cesar C, Krolewiecki A, Cahn P, Wolff M, Pape JW, Padgett D, Madero JS, et al: Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean. J Acquir Immune Defic Syndr. 2009, 51 (5): 615-623. 10.1097/QAI.0b013e3181a44f0a. · DOI
  42. Clark JL, Long CM, Giron JM, Cuadros JA, Caceres CF, Coates TJ, Klausner JD: Partner notification for sexually transmitted diseases in Peru: knowledge, attitudes, and practices in a high-risk community. Sex Transm Dis. 2007, 34 (5): 309-313. · DOI
  43. Furin JJ, Behforouz HL, Shin SS, Mukherjee JS, Bayona J, Farmer PE, Kim JY, Keshavjee S: Expanding global HIV treatment: case studies from the field. Ann N Y Acad Sci. 2008, 1136: 12-20. 10.1196/annals.1425.004. · doi:10.1196/annals.1425.004
  44. Curioso WH, Kurth AE: Access, use and perceptions regarding Internet, cell phones and PDAs as a means for health promotion for people living with HIV in Peru. BMC Med Inform Decis Mak. 2007, 7: 24-10.1186/1472-6947-7-24. · DOI
  45. Bastos FI, Caceres C, Galvao J, Veras MA, Castilho EA: AIDS in Latin America: assessing the current status of the epidemic and the ongoing response. Int J Epidemiol. 2008, 37 (4): 729-737. · DOI
  46. Curioso WH, Kurth AE, Cabello R, Segura P, Berry DL: Usability evaluation of Personal Digital Assistants (PDAs) to support HIV treatment adherence and safer sex behavior in Peru. AMIA Annu Symp Proc. 2008, 918:
  47. Kurth AE, Curioso WH, Ngugi E, McClelland L, Segura P, Cabello R, Berry DL: Personal digital assistants for HIV treatment adherence, safer sex behavior support, and provider training in resource-constrained settings. AMIA Annu Symp Proc. 2007, 1018:
  48. Lopez De Castilla D, Verdonck K, Otero L, Iglesias D, Echevarria J, Lut L, Gotuzzo E, Seas C: Predictors of CD4+ cell count response and of adverse outcome among HIV-infected patients receiving highly active antiretroviral therapy in a public hospital in Peru. Int J Infect Dis. 2008, 12 (3): 325-331. 10.1016/j.ijid.2007.09.008. · doi:10.1016/j.ijid.2007.09.008
  49. Corey DM, Kim HW, Salazar R, Illescas R, Villena J, Gutierrez L, Sanchez J, Tabet SR: Brief report: effectiveness of combination antiretroviral therapy on survival and opportunistic infections in a developing world setting: an observational cohort study. J Acquir Immune Defic Syndr. 2007, 44 (4): 451-455. 10.1097/QAI.0b013e31802f8512. · doi:10.1097/qai.0b013e31802f8512
  50. Cohen J: HIV/AIDS: Latin America & Caribbean. Peru: universal access: more goal than reality. Science. 2006, 313 (5786): 489-10.1126/science.313.5786.489. · doi:10.1126/science.313.5786.489

Cited by

See all 176

Metadata

Authors
Rath, B. A., von Kleist, M., Castillo, M. E., Kolevic, L., Caballero, P., Soto-Castellares, G., Amedee, A. M., Robinson, J. E., Katzenstein, D. K., Van Dyke, R. B., & Oberhelman, R. A.
Venue
BMC Infectious Diseases
Published
2013-01-02
Volume
13
Issue
1
Pages
1-1
ISSN
1471-2334 (ISSN-L)
OpenAlex
W1967279532
Cited by
176
References
1
FWCI
8.30
Type
journal article
Language
en
Open access
gold
Licence
creativecommons.org/licenses/by/2.0 (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antiviral Resistance and Correlates of Virologic Failure in the first Cohort of HIV-Infected Children Gaining Access to Structured Antiretroviral Therapy in Lima, Peru: A Cross-Sectional Analysis. https://app.cochat.ai/papers/10.1186/1471-2334-13-1
The paper
Rath, B. A., von Kleist, M., Castillo, M. E., Kolevic, L., Caballero, P., Soto-Castellares, G., Amedee, A. M., Robinson, J. E., Katzenstein, D. K., Van Dyke, R. B., & Oberhelman, R. A. (2013). Antiviral Resistance and Correlates of Virologic Failure in the first Cohort of HIV-Infected Children Gaining Access to Structured Antiretroviral Therapy in Lima, Peru: A Cross-Sectional Analysis. BMC Infectious Diseases. https://doi.org/10.1186/1471-2334-13-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.